Page of

Laureate 2017

2017 Prix Galien USA - Biotech Award - SPINRAZA

Is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

Previous Next

Laureate 2017

2017 Prix Galien - Pharma Award - VENCLEXTA

Is a BCL-2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy.This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Next Previous